title: [An experimental study on a slow-release complex with rifampicin-polylactic-co-glycolic acid-calcium  phosphate cement].
abstract: OBJECTIVE
  To prepare the slow-release complex with rifampicin (RFP)-polylactic-co-glycolic acid (PLGA)-calcium phosphate cement (CPC) (RFP-PLGA-CPC complex), and to study its physical and chemical properties and drug release properties in vitro.
  
  
  METHODS
  The emulsification-solvent evaporation method was adopted to prepare rifampicin polylactic acid-glycolic acid (RFP-PLGA) slow-release microspheres, which were divided into 3 groups: a calcium phosphate bone cement group (CPC group), a CPC embedded with RFP group (RFP-CPC group), and a PLGA slow-release microspheres carrying RFP and the self-curing CPC group (RFP- PLGA-CPC complex group). The solidification time and porosity of materials were determined. The drug release experiments in vitro were carried out to observe the compressive strength, the change of section morphology before and after drug release.
  
  
  RESULTS
  The CPC group showed the shortest solidification time, while the RFP-PLGA-CPC complex group had the longest one. There was statistical difference in the porosity between the CPC group and the RFP-CPC group (P<0.05); Compared to the RFP-PLGA-CPC complex group, the porosity in the CPC group and the RFP-CPC group were significantly changed (both P<0.01). There was significant difference in the compressive strength between the RFP- PLGA-CPC complex group and the CPC group (P<0.01), while there was significant difference in the compressive strength between the RFP-CPC group and the CPC group (3 days: P<0.05; 30 and 60 days: P<0.01). The change of the compressive strength in the CPC was not significant in the whole process of degradation. The sizes of PLGA microspheres were uniform, with the particle size between 100-150 μm. The microspheres were spheres or spheroids, and their surface was smooth without the attached impurities. There was no significant change in the section gap in the CPC group after soaking for 3 to 60 days. The microstructure change in the RFP-CPC group was small, and the cross section was formed by small particles. The pores of section in the RFP-PLGA-CPC complex group increased obviously, and PLGA microspheres gradually disappeared until the 60th day when there were only empty cavities left. The RFP-PLGA-CPC complex group had no obvious drugs sudden release, and the cumulative drug release rate was nearly 95% in the 60 days. The linear fitting was conducted for the drug release behavior of the complex, which was in accordance with zero order kinetics equation F=0.168×t.
  
  
  CONCLUSIONS
  The porosity of RFP-PLGA-CPC complex is significantly higher than that of CPC, and it can keep slow release of the effective anti-tuberculosis drugs and maintain a certain mechanical strength for a long time.
authors.affiliation: Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha 410008, China wujianhuang11@126.com.
authors.forename: Jianhuang
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Orthopaedics, Third Hospital of Changsha, Changsha 410015, China.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Ding
authors.affiliation: Department of Orthopaedics, Third Hospital of Changsha, Changsha 410015, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Lei
authors.affiliation: Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Miao
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Liang
authors.affiliation: Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Lu
mesh_terms: D001843:Bone Cements / Q000493:pharmacokinetics; D002130:Calcium Phosphates / Q000493:pharmacokinetics*; D019245:Compressive Strength; D003692:Delayed-Action Preparations / Q000493:pharmacokinetics*; D003738:Dental Cements / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000493:pharmacokinetics*; D008422:Materials Testing; D008863:Microspheres; D011100:Polyglycolic Acid / Q000493:pharmacokinetics*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D016062:Porosity; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D001843:Bone Cements; D002130:Calcium Phosphates; D003692:Delayed-Action Preparations; D003738:Dental Cements; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C020243:calcium phosphate; D012293:Rifampin